EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combating multidrug-resistant Klebsiella pneumoniae : current therapeutic regimens and future directions

Robiul Islam, Shyamal C Das, Daniel Pletzer

Journal of Antimicrobial Chemotherapy · 02.02.2026 · 81 (3)

DOI: 10.1093/jac/dkag064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.02.2026. Verfasst von Robiul Islam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Klebsiella pneumoniae, Anti-Bacterial Agents, Klebsiella Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Klebsiella pneumoniae is a major cause of hospital-acquired pneumonia and a critical global threat due to its escalating multidrug resistance. This review highlights current advancements in therapeutic strategies, including double and triple drug combinations, and evaluates their clinical efficacy and limitations. We discuss the global dissemination of resistance determinants such as blaKPC, blaNDM and mcr genes, and the complex mechanisms, including porin mutations, efflux pump overexpression and enzymatic degradation. The regional variation in these mechanisms undermines treatment success. Evidence for antibiotic combination therapy, including the double (colistin/meropenem) and triple (polymyxin B/meropenem/rifampicin) regimens, is analysed, along with controversies regarding their superiority over monotherapy. Finally, we highlight inhaled antibiotic delivery, particularly dry powder inhalers, as a promising strategy to achieve targeted, effective pulmonary drug concentrations and reduced systemic toxicity. Despite progress, significant barriers remain, including formulation stability, regulatory hurdles and the continued shortage of clinical trials. Future research should prioritize optimizing inhaled drug therapies and innovative delivery platforms to combat multidrug-resistant K. pneumoniae lung infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, Multiple, BacterialKlebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsHumansDrug Therapy, CombinationAdministration, Inhalation

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Faculty of Biomedical Sciences, University of Otago, Dunedin 9054, New Zealand.
  • School of Pharmacy, Faculty of Health Professional Programmes, University of Otago, Dunedin 9054, New Zealand.

Zitieren

APA

Islam, R., Das, S. C., & Pletzer, D. (2026). Combating multidrug-resistant Klebsiella pneumoniae : current therapeutic regimens and future directions. Journal of Antimicrobial Chemotherapy, 81(3). https://doi.org/10.1093/jac/dkag064

Vancouver

Islam R, Das SC, Pletzer D. Combating multidrug-resistant Klebsiella pneumoniae : current therapeutic regimens and future directions. Journal of Antimicrobial Chemotherapy. 2026;81(3). doi:10.1093/jac/dkag064

BibTeX
@article{Islam2026,
  author = {Islam, Robiul and Das, Shyamal C and Pletzer, Daniel},
  title = {Combating multidrug-resistant Klebsiella pneumoniae : current therapeutic regimens and future directions},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {3},
  doi = {10.1093/jac/dkag064}
}
Kostenlos starten →